PapersPMID:24445038
Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial.
- 01 · findings
- 3
- 02 · compound
- 1
- 03 · endpoints
- 3
- 04 · null
- 0
curcumin- Population, every finding
- adults with type 2 diabetes
What moved
3 findingsHow to read these marks →curcumin — increases serum adiponectin
very limitedFindingreplicated ×3
“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. - Study
- RCT
- Duration
- 6 months
curcumin — decreases pulse wave velocity (segment unspecified)
very limitedFinding
“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. - Study
- RCT
- Duration
- 6 months
curcumin — decreases serum leptin
very limitedFindingreplicated ×3
“Our results showed that curcumin intervention significantly reduced pulse wave velocity, increased level of serum adiponectin and decreased level of leptin.”
Quoted verbatim from Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. - Study
- RCT
- Duration
- 6 months
Study record
- Read under
- curcumin
- Design
- randomised controlled trial
- Species
- human
- Population
- adults with type 2 diabetes
- Participants
- not recorded
- Comparator
- placebo
- Duration
- 180 days
- Endpoints measured
- 8
- Record
- extracted
- Readings recorded
- 2